Pentostatin, Cyclophosphamide and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903)
Sanford Kempin, Zhuoxin Sun, Neil E. Kay, Elisabeth M. Paietta, Joseph J. Mazza, Rhett P. Ketterling, Olga Frankfurt, David F. Claxton, Joel N. Saltzman, Gordan Srkalovic, Natalie S. Callander, Gerald Gross, Martin S Tallman;Sanford Kempin;Zhuoxin Sun;Neil E. Kay;Elisabeth M. Paietta;Joseph J. Mazza;Rhett P. Ketterling;Olga Frankfurt;David F. Claxton;Joel N. Saltzman;Gordan Srkalovic;Natalie S. Callander;Gerald Gross;Martin S Tallman;
acta haematologica2019Vol. 142pp. 224-
219
tallman2019actapentostatin,
Abstract
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from salvage chemoimmunotherapy (CIT). To explore further the use of CIT in the pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utilizing ...